Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation [PDF]
Acta Dermato-VenereologicaPsoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus.
Chih-Tsung Hung +5 more
doaj +3 more sources
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]
PLoS ONE, 2016 Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw +11 more
doaj +2 more sources
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS [PDF]
Trakia Journal of Sciences, 2023 Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and ...
M. Ganeva
doaj +2 more sources
Dipeptidyl peptidase 4 inhibitors in modern domestic practice
Медицинский совет, 2020 The choice of treatment of diabetes mellitus type 2 is personalized, based on modern Russian and international algorithms for management of such patients.
A. S. Ametov +2 more
doaj +3 more sources
Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin
Journal of Pharmacological Sciences, 2011 .: Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β ...
Masayuki Uchida +2 more
doaj +2 more sources
Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
Drug Design, Development and Therapy, 2015 Watshara Shoombuatong,1 Veda Prachayasittikul,1,2 Nuttapat Anuwongcharoen,1 Napat Songtawee,1 Teerawat Monnor,1 Supaluk Prachayasittikul,1 Virapong Prachayasittikul,2 Chanin Nantasenamat1,2 1Center of Data Mining and Biomedical Informatics, 2Department ...
Shoombuatong W +7 more
doaj +1 more source
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2013 BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang +8 more
doaj +1 more source
Endocrinology, Diabetes & Metabolism, 2021 Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna +7 more
doaj +1 more source
The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020 Background: Dipeptidyl peptidase-4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was found out more than four decades ago as a serine protease that severs N-terminal dipeptides from peptide substrates. DPP-4 inhibitors have been used in many animal models of lung and
Song-Chol Mun, Hye-Sun Hong
doaj +1 more source
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Molecules, 2022 In recent years, important changes have occurred in the field of diabetes treatment. The focus of the treatment of diabetic patients has shifted from the control of blood glucose itself to the overall management of risk factors, while adjusting blood ...
Ruili Yin +4 more
doaj +1 more source